Merck & Co. Acquires German Start-Up Rigontec with Aim of Advancing Immuno-Oncology Success
By Natasha Piper
Pharma Deals Review: Vol 2017 Issue 9 (Table of Contents)
Published: 19 Sep-2017
DOI: 10.3833/pdr.v2017.i9.2274 ISSN: 1756-7874
Section: Mergers & Acquisitions
Fulltext:
Abstract
Merck & Co has agreed to acquire Rigontec, an early phase immuno-oncology biotech, for an upfront payment of €115 M (US$137 M)...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS